Concepts (118)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 11 | 2022 | 87 | 2.900 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 9 | 2022 | 20 | 1.810 |
Why?
|
| Immunologic Factors | 5 | 2021 | 49 | 1.580 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2021 | 144 | 1.000 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 2 | 2021 | 3 | 0.820 |
Why?
|
| Medication Adherence | 1 | 2021 | 48 | 0.680 |
Why?
|
| Peptides | 4 | 2019 | 288 | 0.510 |
Why?
|
| Macula Lutea | 1 | 2011 | 5 | 0.370 |
Why?
|
| Retinal Neurons | 1 | 2011 | 13 | 0.370 |
Why?
|
| Nerve Fibers | 1 | 2011 | 53 | 0.370 |
Why?
|
| Histamine Antagonists | 1 | 2010 | 3 | 0.340 |
Why?
|
| Erythema | 1 | 2010 | 4 | 0.330 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 148 | 0.330 |
Why?
|
| Middle Aged | 12 | 2024 | 7138 | 0.310 |
Why?
|
| Arteries | 1 | 2009 | 65 | 0.300 |
Why?
|
| Adult | 12 | 2024 | 7740 | 0.300 |
Why?
|
| Humans | 21 | 2024 | 28097 | 0.290 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 2 | 2024 | 14 | 0.260 |
Why?
|
| Female | 14 | 2024 | 15156 | 0.240 |
Why?
|
| Neuromyelitis Optica | 1 | 2024 | 7 | 0.220 |
Why?
|
| Male | 10 | 2024 | 13491 | 0.210 |
Why?
|
| Proteomics | 1 | 2024 | 181 | 0.200 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 283 | 0.190 |
Why?
|
| Interferon-beta | 2 | 2015 | 40 | 0.180 |
Why?
|
| Disability Evaluation | 1 | 2021 | 53 | 0.180 |
Why?
|
| Insurance Claim Review | 1 | 2021 | 11 | 0.180 |
Why?
|
| H-Reflex | 1 | 2020 | 4 | 0.170 |
Why?
|
| Databases, Factual | 1 | 2021 | 253 | 0.160 |
Why?
|
| Varicella Zoster Virus Infection | 1 | 2019 | 1 | 0.160 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2019 | 19 | 0.160 |
Why?
|
| Disease Progression | 1 | 2021 | 473 | 0.160 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 28 | 0.160 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2019 | 27 | 0.160 |
Why?
|
| Bicycling | 1 | 2019 | 41 | 0.160 |
Why?
|
| Herpesvirus 4, Human | 1 | 2019 | 42 | 0.160 |
Why?
|
| Leg | 1 | 2019 | 134 | 0.150 |
Why?
|
| Cross-Sectional Studies | 3 | 2011 | 961 | 0.150 |
Why?
|
| Young Adult | 4 | 2021 | 2733 | 0.150 |
Why?
|
| Cognition | 1 | 2021 | 324 | 0.150 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1998 | 5 | 0.140 |
Why?
|
| Cranial Nerve Diseases | 1 | 1998 | 10 | 0.140 |
Why?
|
| Adolescent | 4 | 2021 | 3122 | 0.140 |
Why?
|
| Eye Diseases | 1 | 1998 | 31 | 0.140 |
Why?
|
| Muscle Strength | 1 | 2019 | 230 | 0.140 |
Why?
|
| Central Nervous System | 1 | 2017 | 38 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 1998 | 66 | 0.140 |
Why?
|
| Glatiramer Acetate | 3 | 2015 | 4 | 0.140 |
Why?
|
| Postural Balance | 2 | 2020 | 41 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2017 | 612 | 0.120 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2015 | 30 | 0.120 |
Why?
|
| United States | 1 | 2021 | 2146 | 0.120 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 1013 | 0.110 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2015 | 49 | 0.110 |
Why?
|
| Self Administration | 2 | 2010 | 23 | 0.100 |
Why?
|
| Autoimmunity | 1 | 2015 | 157 | 0.100 |
Why?
|
| Vaccination | 1 | 2014 | 186 | 0.100 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2019 | 991 | 0.090 |
Why?
|
| Tomography, Optical Coherence | 1 | 2011 | 91 | 0.090 |
Why?
|
| Recurrence | 2 | 2022 | 322 | 0.090 |
Why?
|
| Patient Compliance | 1 | 2010 | 75 | 0.080 |
Why?
|
| Placebos | 1 | 2010 | 48 | 0.080 |
Why?
|
| Injections, Subcutaneous | 1 | 2010 | 60 | 0.080 |
Why?
|
| Medical Records | 1 | 2010 | 51 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2010 | 189 | 0.080 |
Why?
|
| Compliance | 1 | 2009 | 21 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2009 | 433 | 0.070 |
Why?
|
| Autoantibodies | 2 | 2024 | 474 | 0.070 |
Why?
|
| Interferon beta-1a | 2 | 2020 | 4 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2019 | 722 | 0.060 |
Why?
|
| Aquaporin 4 | 1 | 2024 | 3 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2022 | 271 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2020 | 4 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 102 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2019 | 72 | 0.040 |
Why?
|
| Electromyography | 1 | 2020 | 175 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 47 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2019 | 79 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 276 | 0.040 |
Why?
|
| Biomarkers | 1 | 2022 | 765 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2019 | 181 | 0.040 |
Why?
|
| Epitopes | 1 | 2019 | 184 | 0.040 |
Why?
|
| Exercise Test | 1 | 2019 | 248 | 0.040 |
Why?
|
| Autoantigens | 1 | 2019 | 212 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 371 | 0.040 |
Why?
|
| Mice | 2 | 2019 | 4654 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2024 | 2546 | 0.030 |
Why?
|
| Time Factors | 2 | 2014 | 1592 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 634 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2010 | 1248 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 1998 | 215 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2015 | 8 | 0.030 |
Why?
|
| Spleen | 1 | 2015 | 112 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2015 | 72 | 0.030 |
Why?
|
| Tetanus Toxoid | 1 | 2014 | 5 | 0.030 |
Why?
|
| Hemocyanins | 1 | 2014 | 7 | 0.030 |
Why?
|
| Natalizumab | 1 | 2014 | 3 | 0.030 |
Why?
|
| Aged | 1 | 2024 | 5400 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2015 | 140 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 1461 | 0.030 |
Why?
|
| Immunologic Memory | 1 | 2014 | 58 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 202 | 0.030 |
Why?
|
| Animals | 2 | 2019 | 10423 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 507 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2010 | 2379 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 632 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2011 | 25 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2011 | 18 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2011 | 32 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 1576 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 741 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 474 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 1435 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2007 | 44 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2007 | 27 | 0.020 |
Why?
|
| North America | 1 | 2007 | 40 | 0.020 |
Why?
|
| Europe | 1 | 2007 | 98 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 971 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 607 | 0.020 |
Why?
|